Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum

Oragenics plans to showcase its ONP-002 intranasal concussion program and device design at a specialized nasal drug delivery industry forum.

Rhea-AI Summary

Oragenics (OGEN) will have Chief Medical Officer James P. Kelly, MD, present ONP-002 intranasal concussion program at the IPAC-RS 2026 Nasal Innovation Forum on September 17, 2026.

The talk, in the Successful Case Studies session at 9:40 AM ET, will cover development and clinical translation of ONP-002, its proposed neuroprotective mechanism, and the company’s proprietary breath-powered intranasal delivery device. ONP-002 is a powder formulated for targeted delivery to the superior nasal roof to reach the brain while minimizing systemic exposure. A Phase IIa feasibility trial is enrolling at three sites in Australia, and an IND submission for anticipated U.S. development is planned for Q4 2026.

Key Terms

phase iia, investigational new drug (ind), cerebral edema, oxidative stress

4 terms

phase iia medical

"including the intranasal delivery platform, Phase IIa trial design"

Phase IIa is an early mid-stage clinical study that tests whether a new drug or treatment shows the intended biological effect in patients and helps identify the best dose. Think of it as a focused test-drive to see if a medicine does what it’s supposed to and what dose is tolerable before larger trials. Investors watch Phase IIa results because positive findings reduce technical risk and can materially increase the program’s value, while negative results raise the likelihood of costly delays or failure.

investigational new drug (ind) regulatory

"advancing its Investigational New Drug (IND) application"

An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.

cerebral edema medical

"reduce neuroinflammation, oxidative stress, and cerebral edema"

Cerebral edema is swelling of the brain caused by excess fluid, like a sponge expanding inside a closed jar. It can impair brain function and be life-threatening, so its occurrence or risk is closely watched in drug trials and medical-device testing. For investors, reports of cerebral edema can influence regulatory decisions, product labels, potential liability and market value because they affect a therapy’s safety profile, development timeline and commercial prospects.

oxidative stress medical

"reduce neuroinflammation, oxidative stress, and cerebral edema"

Oxidative stress is a biological imbalance where damaging, unstable molecules overwhelm the body’s neutralizing defenses, similar to how rust forms when metal is exposed to oxygen and moisture. Investors should care because oxidative stress is linked to many diseases and aging processes, influencing demand for drugs, diagnostics, supplements, and healthcare spending, and it can affect the commercial value and regulatory outlook of related products.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Presentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment

• James P. Kelly, MD, Chief Medical Officer of Oragenics, is scheduled to present in the Successful Case Studies session at the IPAC-RS 2026 Nasal Innovation Forum on Thursday, September 17, 2026
• Presentation is expected to address development and clinical translation of ONP-002, including the intranasal delivery platform, Phase IIa trial design, and anticipated path to U.S. clinical development
• Forum convenes leading pharmaceutical scientists, device developers, and regulators focused on nasal drug delivery

SARASOTA, Fla., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that James P. Kelly, MD, Chief Medical Officer, is scheduled to present at the IPAC-RS 2026 Nasal Innovation Forum on Thursday, September 17, 2026. The event is being held September 16–17, 2026, at Liberty House in Jersey City, New Jersey.

Dr. Kelly is scheduled to present during Session 4: Successful Case Studies, beginning at 9:40 AM ET. His presentation is expected to address the development and clinical translation of ONP-002, Oragenics’ first-in-class intranasal neurosteroid candidate for the treatment of concussion — a condition with no currently approved pharmacological treatments.

The presentation is expected to highlight the scientific rationale underlying ONP-002’s proposed mechanism of action, including its potential ability to reduce neuroinflammation, oxidative stress, and cerebral edema through the proposed simultaneous activation of multiple neuroprotective pathways. Dr. Kelly is expected to discuss the design of the Company’s proprietary breath-powered intranasal delivery device, the ongoing Phase IIa feasibility trial in Australia, and the clinical design framework for anticipated U.S. development.

ONP-002 is manufactured as a powder and delivered via a lightweight intranasal device engineered to direct the drug to the superior nasal roof for direct olfactory nerve, brain delivery, minimizing systemic exposure. A Phase IIa feasibility trial is currently enrolling at three sites in Australia, and the Company is advancing its Investigational New Drug (IND) application, with submission anticipated in Q4 2026.

Dr. Kelly stated, “The IPAC-RS Nasal Innovation Forum is an ideal venue to share the science underpinning our intranasal platform with the formulation, device, and regulatory community. Concussion represents a significant unmet need, and we are excited to present our progress toward potentially bringing the first pharmacological treatment for this condition to patients.”

The IPAC-RS Nasal Innovation Forum is an annual pharmaceutical industry forum dedicated to nasal drug delivery, convening scientists, device innovators, and regulatory experts to discuss formulation science, device technology, manufacturing best practices, and regulatory strategy.

About ONP-002

ONP-002 is a first-in-class intranasal neurosteroid being investigated for the treatment of mTBI (concussion). There are currently no FDA-approved pharmacological treatments for mTBI. ONP-002 is designed to reduce neuroinflammation, oxidative stress, and cerebral edema through gene amplification of multiple neuroprotective pathways simultaneously. The compound is spray-dry manufactured into a nanoparticle powder and delivered via a proprietary breath-powered intranasal device designed to maximize olfactory deposition and direct brain delivery while minimizing systemic exposure. Phase I single and multiple ascending dose safety trials have been completed with a favorable safety and tolerability profile. A Phase IIa feasibility trial is currently enrolling in Australia.

About Oragenics

Oragenics is a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology. The Company’s lead candidate, ONP-002, is being developed as a potential first-in-class treatment for mTBI (concussion). Oragenics is advancing ONP-002 through Phase IIa clinical trials in Australia, with U.S. Phase IIb trials planned to follow pending IND submission. The Company’s intranasal delivery platform has potential applications across a range of acute and chronic neurological conditions. For more information, visit www.oragenics.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements concerning the Company’s expectations, plans, business outlook, or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance, or other matters are forward-looking statements. These statements include, but are not limited to, statements regarding the expected timing and outcomes of the Company’s Phase IIa and planned Phase IIb clinical trials, the Company’s regulatory strategy and engagement with the FDA, the anticipated timing of the Company’s IND submission, the potential applications of Oragenics’ intranasal delivery platform, and the Company’s ability to advance its clinical programs with available capital. These forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including risks related to the clinical development process, patient enrollment and trial execution, regulatory approval processes, the Company’s ability to secure adequate funding for operations, and those risks set forth in Oragenics’ most recent Forms 10-K, 10-Q, and other SEC filings available through EDGAR at www.sec.gov. Oragenics undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of this press release, except as may be required by law.

CONTACTS
Investor Relations
irth Communications
1-866-976-4784
IR@oragenics.com

Media Relations
irth Communications
1-866-976-4784
media@irthcommunications.com

Source: Oragenics